Testing a new gene therapy injection for hard-to-treat autoimmune diseases

This is an early-stage clinical trial testing a new treatment called V001-BCMA, which is a gene therapy delivered by injection directly into the body. The trial aims to evaluate whether this medication is safe and effective for people with five different hard-to-treat autoimmune diseases: systemic lupus erythematosus, IgG4-related disease, systemic sclerosis, inflammatory myopathy, and ANCA-associated vasculitis. The researchers want to understand how well this treatment works and what side effects it may cause.

Many people with these autoimmune diseases do not respond well enough to standard treatments like steroids and immunosuppressants, or they cannot tolerate these medications. This trial exists to explore whether this new targeted gene therapy approach could offer hope for patients whose diseases remain active despite current treatments.